Bionxt signs LOI for rights to drug chaperone technology

Executive Summary

• Bionxt Solutions Inc. has signed a non-binding letter of intent (LOI) to secure exclusive rights to advanced drug chaperone technology for oral-dissolvable applications from a third-party biotechnology developer.
• The transaction aims to enhance Bionxt’s proprietary oral-dissolvable thin-film (ODF) platform by improving drug stability, absorption efficiency, and formulation performance, particularly for neurological and chronic disease indications.
• The deal includes exclusive rights for oral-dissolvable applications, with Bionxt owning all related intellectual property, and provides a right of first refusal for non-oral delivery formats.

Key Details

• Transaction Structure: Non-binding letter of intent for a proposed transaction to acquire exclusive rights to variable-affinity drug chaperone technology.
• Technology Focus: Chaperone-enabled targeted delivery designed to improve performance through controlled and consistent delivery at the site of administration without chemical modification of the active pharmaceutical ingredient.
• Strategic Benefits:
  • Enhances drug stability, absorption efficiency, and delivery consistency.
  • Expands the range of drug candidates that can be reformulated into fast-dissolving, swallow-free formats.
  • Strengthens platform differentiation and intellectual property positioning.
  • Supports life-cycle management and commercial potential in neurological and other chronic disease indications.
• Intellectual Property: Bionxt will own all related IP within the defined field of use. The roadmap includes prototype development and future patent filings in key jurisdictions (Europe and the United States).
• Future Optionality: The LOI grants Bionxt a right of first refusal to evaluate the acquisition of rights for non-oral delivery formats.
• Financing: Bionxt intends to finance all development activities internally.
• Status: The transaction is subject to the negotiation and execution of definitive agreements; no assurance that agreements will be completed.

Notable Quotes

• "This initiative is strategically important for Bionxt," said Hugh Rogers, chief executive officer of Bionxt Solutions. "By securing rights to chaperone-enabled delivery technology, we are strengthening our oral thin-film platform and expanding the range of drug candidates that can be effectively reformulated into fast-dissolving, swallow-free formats, including therapies for neurological diseases where consistent absorption and patient adherence are critical. This supports a scalable, IP-driven [intellectual property] growth strategy and enhances our long-term commercial potential."